Literature DB >> 9809977

Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line.

L S Grauer1, K D Lawler, J L Marignac, A Kumar, A S Goel, R L Wolfert.   

Abstract

An alternatively spliced variant of prostate-specific membrane antigen (PSMA) designated PSM' was originally described following identification of its mRNA in normal prostate. We have purified the PSM' protein from LNCaP cells using two immunoaffinity columns in tandem. The first column contained a monoclonal antibody (7E11) that was reactive with the NH2 terminus of PSMA, which specifically depleted the LNCaP lysate of full-length PSMA. The nonbinding fraction was then passed over a second column composed of a monoclonal antibody (PEQ226.5), the epitope of which was located within the 134-437 domain of PSMA and shared with PSM'. The protein eluted from the second immunoaffinity column produced a Mr 95,000 band on SDS-PAGE, which was slightly lower than the full-length PSMA at Mr 100,000. The band was NH2-terminally sequenced through 15 residues, and the assigned sequence coincided with the predicted sequence for PSM' protein minus the first two NH2 terminus amino acids. The PSM' protein, therefore, began with residue 60 of PSMA (alanine). LNCaP cells were fractionated, and PSM' was localized to the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809977

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

3.  Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2011-10-04       Impact factor: 2.823

Review 4.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

Review 5.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Authors:  Ronnie C Mease; Catherine A Foss; Martin G Pomper
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 6.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives.

Authors:  Valerie Humblet; Preeti Misra; John V Frangioni
Journal:  Contrast Media Mol Imaging       Date:  2006 Sep-Oct       Impact factor: 3.161

8.  Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Lisa Y Wu; Jeonghoon Lee; Peter T A Reilly; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

9.  Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood.

Authors:  Matthias Jost; John R Day; Ryan Slaughter; Theodore D Koreckij; Deanna Gonzales; Martin Kinnunen; Jack Groskopf; Harry G Rittenhouse; Robert L Vessella; Mark A Reynolds
Journal:  Mol Cancer       Date:  2010-07-02       Impact factor: 27.401

10.  A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Authors:  P Bühler; P Wolf; D Gierschner; I Schaber; A Katzenwadel; W Schultze-Seemann; U Wetterauer; M Tacke; M Swamy; W W A Schamel; U Elsässer-Beile
Journal:  Cancer Immunol Immunother       Date:  2007-06-20       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.